Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
STIMULON cpcQS-21
- Development stage
- Unknown
- Lead developer
- SaponiQx
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular, Subcutaneous
01
Overview
STIMULON cpcQS-21 is a proprietary vaccine adjuvant consisting of the saponin QS-21 produced via cultured plant cells rather than traditional extraction from Quillaja saponaria tree bark. Developed by SaponiQx (a subsidiary of Agenus), this formulation offers a sustainable and scalable alternative to conventional sources, ensuring consistent quality and supply. As an adjuvant, it is designed to enhance both humoral and cellular immune responses when combined with antigens in vaccines. Mechanistically, QS-21 acts primarily on antigen-presenting cells—facilitating antigen uptake by dendritic cells and activating the NLRP3 inflammasome pathway to promote pro-inflammatory cytokine release (IL‑1β, IL‑18). It is a key component in several leading vaccine adjuvant systems such as AS01 (used in GSK’s Shingrix and Arexvy vaccines) and has demonstrated robust immunostimulatory activity across numerous clinical trials[3][6][8][10]. The cultured plant cell production method enables large-scale manufacturing for research or commercial use.
- Brand names
- STIMULON cpcQS-21
- Other names
- cultured plant cell QS-21QS-21 (cultured plant cell)STIMULON QS-21 (cultured plant cell)
02
Targets
NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)
Beyond the preview
Go deeper on STIMULON cpcQS-21.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on STIMULON cpcQS-21.